On December 16, 2022 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "the Company") reported that it has decided to terminate its sponsored ADR (American Depositary Receipt) program on January 31, 2023 (Press release, Eisai, DEC 15, 2022, View Source [SID1234625301]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company established its sponsored ADR program in 1995 to improve the convenience for investors in the United States. However, as it became easier for foreign investors to have access to the Japanese stock market directly, with the increasing internationalization of the Japanese financial and securities markets, the Company has decided to terminate the program.